Published in final edited form as:

J Addict Med. 2018 ; 12(1): 31–39. doi:10.1097/ADM.0000000000000360.

Physicians' Decision-making When Implementing Buprenorphine with New Patients: Conjoint Analyses of Data from a Cohort of Current Prescribers

Hannah K. Knudsen, PhD*,

Department of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky

Michelle R. Lofwall, MD,

Department of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky

Sharon L. Walsh, PhD,

Department of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky

Jennifer R. Havens, PhD, and

Department of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky

Jamie L. Studts, PhD

Department of Behavioral Science, University of Kentucky

Abstract

Objectives—Few studies have considered how providers make decisions to prescribe buprenorphine to new patients with opioid use disorder. This study examined the relative importance of patients' clinical, financial, and social characteristics on physicians' decision-making related to willingness to prescribe buprenorphine to new patients and the number of weeks of medication that they are willing to initially prescribe after induction.

Methods—A national sample of 1,174 current prescribers was surveyed. Respondents rated willingness to prescribe on a 0 to 10 scale and indicated the number of weeks of medication (ranging from none to >4 weeks) for 20 hypothetical patients. Conjoint analysis estimated relative importance scores and part-worth utilities for these two outcome ratings.

Results—The mean rating for willingness to prescribe was 5.52 (SD=2.47), indicating a moderate willingness to implement buprenorphine treatment. The mean prescription length was 2.06 (SD=1.34), which corresponds to 1 week of medication. For both ratings, the largest importance scores were for other risky substance use, method of payment, and spousal

*Corresponding author. Department of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky, 845 Angliana Ave, Room 204, Lexington, KY 40508. Tel: 1-859-323-3947. Fax: 1-859-257-5232. (hannah.knudsen@uky.edu).

Conflicts of Interest

The remaining authors (Hannah Knudsen and Jamie Studts) have no conflicts of interest to declare.

involvement in treatment. Illicit benzodiazepine use, having Medicaid insurance to pay for the office visit, and having an opioid-using spouse were negatively associated with these outcome ratings, while a history of no risky alcohol or benzodiazepine use, cash payment, and having an abstinent spouse were positively associated with both ratings.

Conclusions—Reticence to prescribe to individuals using an illicit benzodiazepine and individuals with a drug-using spouse aligns with practice guidelines. However, reluctance to prescribe to patients with Medicaid may hamper efforts to expand access to treatment.

Untreated opioid use disorder (OUD) is associated with numerous negative consequences, including mortality, acquisition and transmission of HIV and hepatitis C (HCV), and criminal involvement (Volkow et al., 2014). Buprenorphine is effective (Fiellin et al., 2008), but its implementation is sub-optimal (Jones et al., 2015). The current study explores physician decision-making about prescribing buprenorphine for OUD through conjoint analysis, a methodology that uses clinical vignettes to describe the factors influencing choices. Understanding physicians' implementation of buprenorphine is critical given the current US opioid epidemic (Compton et al., 2015).

Research on buprenorphine implementation

Early research on buprenorphine diffusion measured its availability within specialty substance use disorder (SUD) treatment organizations through surveys of leadership (Koch et al., 2006; Friedmann et al., 2010) and counselors (Rieckmann et al., 2011). Within programs offering buprenorphine, just 37% of OUD patients received it (Knudsen et al., 2011), suggesting processes were differentiating which OUD patients were considered appropriate for buprenorphine.

Physician surveys have not addressed how providers make prescribing decisions. Initial surveys identified characteristics differentiating prescribers from waived non-prescribers (Kissin et al., 2006; Thomas et al., 2008). Surveys measured physicians' knowledge and attitudes about buprenorphine (Kissin et al., 2006; Thomas et al., 2008; Netherland et al., 2009; Hutchinson et al., 2014), dosing and counseling practices (Arfken et al., 2010), and perspectives on misuse and diversion (Yang et al., 2013).

A significant question remains as to whether patient-level factors, beyond a diagnosis of OUD, influence prescribing decisions. Alcohol and benzodiazepine use disorder are contraindications because they increase the risk of mortality and relapse (Center for Substance Abuse Treatment, 2004; American Society of Addiction Medicine, 2015). For several years, buprenorphine's impact on hepatic toxicity in patients with HIV or HCV was unknown. Although research has shown buprenorphine is safe for these patients (Vergara-Rodriguez et al., 2011; Saxon et al., 2013), it is unclear whether these findings have diffused to prescribers.

Other clinical characteristics may influence decision-making. Patients who only use prescription opioids stay in buprenorphine treatment longer than those who use heroin (Nielsen et al., 2015). Some studies indicate that buprenorphine has attracted new patients

into treatment (Sullivan et al., 2005), and, for individuals who use prescription opioids, treatment outcomes are better among those who are new to treatment (Dreifuss et al., 2013).

Family support and employment are social factors that may be prognostic indicators of better treatment outcomes. Involving an abstinent spouse in treatment adherence results in superior outcomes in traditional medication management (Galanter et al., 2004). Employed patients are retained longer in buprenorphine treatment (Parran et al., 2010), which may influence physicians' prescribing decisions.

Finally, prescribing decisions may be influenced by how patients intend to pay for the office visits associated with treatment. Buprenorphine providers have substantial concerns about the adequacy of reimbursement (Netherland et al., 2009). In other fields, inadequate reimbursement and cumbersome prior authorization processes are potent barriers to the acceptance of Medicaid (Sommers et al., 2011). Some state Medicaid programs have implemented restrictions on access and duration of buprenorphine treatment (Clark and Baxter, 2013), which may serve as a further deterrent. A disinclination to treat Medicaid patients has heightened significance with Medicaid expansion in many states under the Affordable Care Act (McLellan and Woodsworth, 2014).

Physicians also must decide how many days of medication to prescribe to new patients. Practice guidelines recommend that prescribers initially prescribe no more than a week of medication (Center for Substance Abuse Treatment, 2004) with weekly visits until patients are stable (American Society of Addiction Medicine, 2015). It is not clear whether prescribers adhere to this recommendation or if patient-level characteristics are associated with this initial prescription.

Conjoint Analysis for Studying Decision-Making

Studying physician decision-making is challenging, and historically has relied upon self-report or clinical case vignettes. Seminal research found case vignettes were more accurate than record abstraction and equivalent to using standardized patients when measuring physician behaviors (Peabody et al., 2000).

Conjoint analysis is an extension of case vignettes. It quantifies the relative contributions of *a priori* specific factors in decision-making (Luce and Tukey, 1964; Orme, 2010) through vignettes that provide multiple pieces of information (Ryan and Farrar, 2000; Sattler and Hensel-Borner, 2003). The underlying logic is that individuals typically make decisions by simultaneously evaluating a mixture of attributes that represent a number of trade-offs that are common in real-life choices (Stevens and Jason, 2015). In healthcare, a patient presents for care with a combination of clinical and social attributes. Physicians' decision-making is likely influenced by some attributes more than others. Conjoint analysis estimates the magnitude of influence of the attributes embedded in a series of vignettes. Furthermore, it produces more accurate estimates than asking a series of individual questions of the relative importance of key variables and reduces social desirability bias (Sattler and Hensel-Borner, 2003).

An additional benefit is that software programs allow researchers to deploy orthogonal designs where algorithms efficiently identify the smallest number of vignettes that are needed to understand the relative importance of the included attributes. In contrast, a full factorial design, where all possible combinations of the attributes are shown, can quickly yield an untenable number of vignettes. Orthogonal designs in conjoint surveys increase the feasibility of examining more attributes while reducing participant burden. Although it has been applied to other medical professions (Bachmann et al., 2008), this research is the first known study to apply conjoint analysis to physician decision-making in SUD treatment.

Methods

Sample

A national random sample of buprenorphine prescribers was recruited. The May 2014 issue of the Drug Enforcement Agency's Controlled Substances Act (CSA) Active Registrants database was purchased, and all civilian physicians waived to prescribe buprenorphine (n=24,506) in the 50 US states and the District of Columbia were extracted. Physicians were randomly sampled within states. In a pilot phase, we constructed a simple random sample and discovered some small states were not represented due to chance. Hence, sampling within states ensured the sample would include all states and approximate the proportion of waived physicians in each state.

We randomly sampled 8,031 physicians from the CSA Database for screening. Telephone screening assessed eligibility, as determined by the current treatment of at least one OUD patient with buprenorphine within the sampled state. The CSA Database lacked telephone numbers, so we searched across multiple websites, including SAMSHA's buprenorphine locator, HealthGrades®, Google®, ASAM's website, and the National Provider Index directories. Working telephone numbers were not found for 757 physicians (9.4%), screening was incomplete after 10 attempts for 845 physicians (10.5%), and 444 physicians refused to complete the screening (5.5%). Ineligible physicians included 1,986 with no current patients (24.7%), 386 not practicing in the sampled state (4.8%), and 60 (0.8%) who were not recruited because enrollment targets had already been met in their state. Screening yielded 3,553 eligible physicians (44.2% of those sampled).

Research staff mailed an advance notification letter and then express-mailed a packet approximately one week later containing a study description letter, survey, consent forms, postage-paid envelope, and a form for receiving a \$100 incentive. All physicians were mailed a postcard reminder. After 6 weeks of non-response, staff called the practice and sent a second packet. Between July 2014 and January 2017, 1,174 physicians participated (33.0% response rate). All procedures were consistent with the Helsinki Declaration and were approved by the University of Kentucky's Institutional Review Board (Protocol 13-0068-P6J).

Measures of Physician Characteristics

Several physician characteristics were measured (Table 1). Information regarding waiver type (30 vs. 100 patients) was extracted from the CSA database. Physicians indicated the

settings in which they delivered buprenorphine treatment. Medical specialty was coded into three mutually exclusive groups: addiction (e.g., addiction medicine, addiction psychiatry), psychiatry (with no mention of addiction), and all others. Demographic characteristics included age, gender, and race/ethnicity.

Conjoint Vignettes and Outcome Ratings

The conjoint vignettes consisted of 6 attributes (i.e., variables) with 3 levels (i.e., pieces of information presented in varying combinations) plus one attribute with 2 levels. Development of the attributes and levels was informed by our literature review, qualitative interviews conducted with 21 physician-mentors within the Physician Clinical Support System-Buprenorphine (PCSS-B; now PCSS-MAT), and clinical expertise within our investigative team. This strategy of attribute development is consistent with the literature (Bridges et al., 2011). A full factorial design would have required 1,458 vignettes ($3 \times 3 \times 3 \times 3 \times 2 \times 3 = 1,458$). We used *IBM SPSS*'s conjoint analysis commands to select a representative subset of vignettes using an orthogonal design. Attributes and the number of levels in each attribute were entered using *IBM SPSS*'s "generate orthogonal design" command, which determined the minimum number of vignettes and the composition of each vignette to support later calculations of relative importance scores and part-worth utilities after data collection was completed. Results indicated the survey should include 18 vignettes and specified the seven levels to be depicted within each vignette, which were presented in bullet point format in the survey. *SPSS* also generated 2 additional holdout vignettes for model validation, for a total of 20 vignettes. Table 2 presents the combination of levels within each vignette and the wording of the two outcome ratings (i.e., likelihood of prescribing and weeks of medication initially prescribed) appears in Table 3. Table 4 includes the precise wording of each level (full vignettes are available by request).

Prior to fielding the survey, the vignettes were pilot-tested using cognitive interviewing (Beatty and Willis, 2007). Eight buprenorphine prescribers in Lexington, KY, were recruited and consented. As they completed the vignettes, prescribers were queried by a trained interviewer to identify areas of potential misinterpretation and structural problems that might impede valid survey administration (Willis, 2005). Interviews were audio-recorded and transcribed. Although feedback was generally positive, participants identified some modest wording changes that were incorporated into the vignettes.

Data Management and Statistical Analysis

Data were entered into REDCap (Research Electronic Data Capture), a secure web-based application hosted by the University of Kentucky, that supports validated data entry and automated exporting of data into statistical software (Harris et al., 2009). Descriptive statistics for the two outcome ratings were calculated. *SPSS Conjoint* estimated the part-worth utilities for each of the levels and the average relative importance of the seven attributes. Larger part-worth utilities, which represent regression coefficients, indicate greater influence of attributes on physicians' responses. Our model specified that all levels were categorical and that the outcome ratings represented scores as opposed to ranks. Average relative importance scores sum to 100, allowing comparison of the magnitudes of these scores. They are calculated by first calculating the range in part-worth utilities for each

attribute, then dividing each attribute's range by the sum of these ranges, and multiplying by 100. Preference scores, based on alternative configurations of the part-worth utilities plus the constant, were calculated.

RESULTS

Willingness to prescribe

Across the 20 vignettes, the overall mean for willingness to prescribe buprenorphine was 5.52 (SD=2.47), indicating a moderate willingness to implement buprenorphine. Responses varied across the 20 vignettes, as seen in Table 2. Means ranged from a low of 4.14 (SD 3.62; Patient 13) to a high of 7.62 (SD=2.69; Patient 7). In the Patient 13 vignette, 31.0% of respondents indicated they were not at all willing to prescribe. In contrast, just 4.7% of respondents reported being not at all willing to prescribe to Patient 7.

Relative importance scores appear in Figure 1 (dark gray bars). The attributes with the largest relative importance scores were risky substance use (33.5), method of payment (31.9), and spousal involvement in treatment (21.3). The remaining four attributes of type of opioid/route, treatment history, co-occurring infections, and employment status had importance scores that were small; the sum of these four importance scores was only 13.3.

Part-worth utilities indicated how specific levels within attributes were correlated with willingness to prescribe (Table 3, Rating 1 column). For risky substance use, the large positive part-worth utility for patients with no history of alcohol or benzodiazepine disorders indicated greater willingness of physicians to prescribe to such patients. Weekly binge drinking had a modest negative impact on willingness to prescribe. Weekly illicit alprazolam use had a large negative part-worth utility, indicating much lower willingness to prescribe. For payment, private insurance had little impact on willingness to prescribe. Cash payment had a large positive part-worth utility while having Medicaid yielded a large negative part-worth utility. Finally, physicians were more willing to prescribe when the patient had an abstinent spouse who was willing to supervise dosing. When the patient did not want to disclose to their spouse about their treatment, there was a modest-sized negative part-worth utility. A much larger negative part-worth utility was observed when the patient had a spouse who also used opioids but was not seeking treatment.

Alternative configurations of patient characteristics were then calculated as preference scores to examine the range of willingness to prescribe buprenorphine. When the largest positive utilities were combined with the constant, the preference score for physicians' willingness to prescribe buprenorphine was 7.87. This configuration represented a patient with prescription OUD with non-intravenous use, first time seeking treatment, no other risky substance use, HCV-positive but HIV-negative, a spouse who did not use drugs, employed, and was willing to pay out-of-pocket. When the largest negative utilities were combined, the preference score was just 2.94. In this configuration, the patient characteristics were prescription OUD with intravenous use, fourth time seeking treatment with history of methadone, weekly illicit alprazolam use, HIV-negative and HCV-negative, spouse used opioids and was not seeking treatment, unemployed, and had Medicaid.

Weeks of buprenorphine medication

Physicians were also asked about the number of weeks of medication that they would prescribe (Table 2, Rating 2 column). The mean across the 20 vignettes was 2.06 (SD=1.34), which corresponds most closely to 1 week of medication. In terms of physicians endorsing less than 1 week of medication, prevalence ranged from 12.7% of physicians for Patient 12 to 21.9% of physicians for Patient 19. For longer prescriptions (i.e., two weeks or more), Patient 13 had the least physicians willing to prescribe medication for this longer timeframe (20.0%) and Patient 7 had the most (37.1%).

The results for amount of medication were similar to willingness to prescribe. The three largest relative importance scores (Figure 1, light gray bars) were for risky substance use (33.5), method of payment (31.9), and spousal involvement (21.3). The directions of the part-worth utilities were also similar (Table 3, Rating 2). Physicians would prescribe more medication when the patient had no history of alcohol or benzodiazepine use disorder, but less when the patient reported illicit alprazolam use. Physicians were willing to prescribe more medication to patients paying out-of-pocket, yet less medication to patients with Medicaid. Finally, the part-worth utility was positive when patients had an abstinent spouse who would supervise dosing, and the utility was negative when the spouse used opioids and was not seeking treatment.

Consideration of alternative configurations with the largest all-positive versus all-negative part-worth utilities (plus the constant) did reveal differences in weeks of medication. In the all-negative scenario (i.e., prescription OUD with intravenous use, first treatment, alprazolam use, HIV-positive and HCV-negative, spouse uses opioids and not seeking treatment, unemployed, and Medicaid), the preference score was 1.08, which represented less than 1 week of medication. In the all-positive scenario (i.e., prescription OUD with non-intravenous use, fourth treatment with prior outpatient treatment, no risky substance use, HCV-positive but HIV-negative, spouse does not use drugs, employed, and paying out-of-pocket), the preference score was 2.70, which was between 1 week and 2 weeks of medication.

DISCUSSION

Through vignettes of individuals with OUD presenting for buprenorphine treatment, this study was the first to examine prescriber decision-making using conjoint analysis. Observed data indicated a moderate level of willingness to prescribe buprenorphine, but also notable variability. On average, physicians were willing to prescribe 1 week of medication. About one in five physicians consistently indicated they would prescribe 1 week or less of medication regardless of patient characteristics, but some physicians were willing to prescribe 2 weeks or more of buprenorphine to new patients, which exceeds practice guidelines (Center for Substance Abuse Treatment, 2004; American Society of Addiction Medicine, 2015).

For both outcome ratings, co-occurring substance use had the largest relative importance scores. Specifically, physicians were less willing to prescribe and willing to prescribe fewer weeks of medication to patients reporting illicit alprazolam use. This suggests physicians

may be sensitive to the risk of concomitant use of buprenorphine and a benzodiazepine. It is possible that “illicit” (i.e., prescribed to someone else) sensitized physicians to a behavior that may be a red flag for potential buprenorphine misuse or diversion, both of which are public health concerns (Lofwall and Walsh, 2014).

The second largest factor was the patient’s method of payment for their office visit. Physicians indicated a clear preference for cash-paying patients, while physicians were less willing to prescribe and were willing to prescribe less medication when patients intended to pay with Medicaid. There have been reports of cash-only practices (Torrington et al., 2007), which may reduce the administrative burdens of navigating the complexities of insurance and barriers imposed by lack of parity by some payers (The Mental Health & Substance Use Disorder Parity Task Force, 2016). However, cash-only practices may be detrimental to treatment access for patients with limited economic resources.

The finding regarding Medicaid is troubling given the prediction that the Medicaid expansion under the ACA would reduce treatment barriers (McLellan and Woodworth, 2014). Medicaid expansion has substantially reduced the number of uninsured individuals (Sommers et al., 2015). However, if individuals with Medicaid cannot find buprenorphine providers who will accept their insurance, the expected treatment gains from the ACA will be under-realized. One issue that we cannot address is whether refusing Medicaid patients is an economic decision, reflects stigma about the Medicaid population, or other factors.

Prescribers’ greater willingness to treat patients with abstinent spouses who were willing to supervise dosing is reassuring. It is concordant with published guidelines that patients who have supportive and sufficiently stable psychosocial circumstances are good candidates for office-based buprenorphine treatment (Center for Substance Abuse Treatment, 2004; American Society of Addiction Medicine, 2015). It suggests that such spouses may be a strong network support (Galanter et al., 2004). On the other hand, having a spouse with untreated OUD may pose a risk to safe storage of the medication and increase risk for diversion. Such patients may need closer monitoring and structured treatment with observed dosing (Lofwall and Walsh, 2014). Patients’ social networks influence their drug-taking behavior (Young et al., 2014), which is a reason to be concerned about spouses with untreated OUD.

Identifying factors that do not influence prescribing decisions is also important for equity in treatment access. It was somewhat surprising that decision-making was only minimally impacted by the type of opioid and primary route, as users of prescription opioids may have better outcomes than users of heroin (Nielsen et al., 2015). Previous treatment history was not a substantial driver of physician decision-making. We found minimal evidence of disparities based on HIV or HCV serostatus, which, from the perspective of access to treatment, is favorable. There were minimal differences by employment status.

Several study limitations should be noted. First, conjoint analysis can only speak to the factors explicitly presented in the vignettes. Future research should consider additional factors while retaining the three key characteristics identified in the present study. Such a design could determine whether those new factors are more or less influential than the three

factors identified in our study. Furthermore, future research should consider whether physician and setting characteristics are associated with prescribing decisions; latent class analysis may be useful in such an examination.

Also, our response rate was low, which is common in national studies of physicians (Klabunde et al., 2013). Because this represented a newly recruited sample, we cannot ascertain how respondents may have differed from non-respondents beyond their DEA waiver status. We estimated a mixed effects regression model (not shown) comparing respondents to non-respondents and found that physicians holding the 100-patient waiver were 1.4 times ($p<.001$) more likely to respond than physicians holding the 30-patient waiver. The intraclass coefficient (ICC) for nesting of physicians within states was relatively small (ICC=.040). Unfortunately, *SPSS Conjoint* does not support the weighting of data that would adjust for the differences in response rates by types of participants or the nesting of respondents within clusters. It is also unknown whether other design choices, such as a web-based survey or a larger financial incentive, would have increased response rate. However, research has shown that physicians were less likely to respond to online surveys than mailed surveys (McLeod et al., 2013). Our financial incentive was the maximum amount allowed by our institution in the absence of a Social Security number; obtaining Social Security numbers would increase the risk of identity theft, which we viewed as antithetical to human subjects protections.

Given the opioid crisis in the United States, significant efforts have been undertaken to expand access to evidence-based pharmacotherapies. Our findings highlight considerable variation in physicians' willingness to prescribe buprenorphine as a function of clinical, financial, and social factors. Reticence to prescribe to patients with risk factors, such as ongoing benzodiazepine use or a spouse with untreated OUD, may be rational from the provider's perspective. However, the negative association between Medicaid insurance and willingness to prescribe suggests that policymakers should consider whether restructuring Medicaid would encourage more physicians to accept this form of payment. In the absence of such changes, efforts to expand buprenorphine treatment may stall despite the policy measures, such as the Medicaid expansion, implemented in some states under the ACA.

Acknowledgments

The authors gratefully acknowledge the physicians who participated in the survey and the efforts of Jennifer Cook, Eric Shelton, Diana Norkus, Danielle Rosenkrantz, Jorge Masson, Joseph Calvert, and Haley Clark in recruiting physicians for this study.

Source of Funding

Michelle Lofwall has received contract research funding from Braeburn Pharmaceuticals, has provided consultation for Invidior (which manufactures Suboxone®, a buprenorphine product), and has received honoraria from PCM Scientific, which received unrestricted educational grant funds from Reckitt Benckiser (now Invidior) for developing and delivering educational talks on opioid use disorder. Sharon Walsh has received consulting fees and research support from Braeburn Pharmaceuticals, consulting fees from Camurus, honoraria and travel support from Invidior, and honoraria from PCM Scientific, through an unrestricted educational grant from Reckitt Benckiser, as a speaker and conference organizer. Jennifer Havens has received honoraria from Pinney Associates for serving on an external advisory board focused on buprenorphine misuse and diversion.

This study was supported by a grant from the National Institute on Drug Abuse (NIDA Grant R33DA035641). NIDA had no further role in study design; in the collection, analysis, or interpretation of data; or the preparation of

this manuscript. The study team's use of REDCap was supported by a grant from the National Center for Advancing Translational Sciences (NIH CTSA UL1TR000117) that supports the University of Kentucky's Center for Clinical and Translational Science. The content of this manuscript is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health or NIDA.

References

- American Society of Addiction Medicine. The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioids Chevy Chase. MD: ASAM; 2015.
- Arfken CL, Johanson CE, di Menza S, et al. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. *J Subst Abuse Treat*. 2010; 39:96–104. [PubMed: 20598829]
- Bachmann LM, Muhleisen A, Bock A, et al. Vignette studies of medical choice and judgement to study caregivers' medical decision behaviour: Systematic review. *BMC Med Res Methodol*. 2008; : 8.doi: 10.1186/1471-2288-1188-1150 [PubMed: 18298827]
- Beatty PC, Willis GB. Research synthesis: The practice of cognitive interviewing. *Public Opin Q*. 2007; 71:287–311.
- Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. *Value Health*. 2011; 14:403–413. [PubMed: 21669364]
- Clark RE, Baxter JD. Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good? *JAMA Internal Medicine*. 2013; 173:1571–1572. [PubMed: 23877740]
- Compton WM, Boyle M, Wargo E. Prescription opioid abuse: Problems and responses. *Prev Med*. 2015; 80:5–9. [PubMed: 25871819]
- Dreifuss JA, Griffin ML, Frost K, et al. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. *Drug Alcohol Depend*. 2013; 131:112–118. [PubMed: 23333292]
- Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: Results at 2–5 years. *Am J Addict*. 2008; 17:116–120. [PubMed: 18393054]
- Friedmann PD, Jiang L, Alexander JA. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs. *J Behav Health Serv Res*. 2010; 37:322–337. [PubMed: 19296223]
- Galanter M, Dertatis H, Glickman L, et al. Network therapy: Decreased secondary opioid use during buprenorphine maintenance. *J Subst Abuse Treat*. 2004; 26:313–318. [PubMed: 15182896]
- Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009; 42:377–381. [PubMed: 18929686]
- Hutchinson E, Catlin M, Andrilla CH, et al. Barriers to primary care physicians prescribing buprenorphine. *Ann Fam Med*. 2014; 12:128–133. [PubMed: 24615308]
- Jones CM, Campopiano M, Baldwin G, et al. National and state treatment need and capacity for opioid agonist medication-assisted treatment. *Am J Public Health*. 2015; 105:e55–e63.
- Kissin W, McLeod C, Sonnefeld J, et al. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. *J Addict Dis*. 2006; 25:91–103. [PubMed: 17088229]
- Klabunde CN, Willis GB, Casalino LP. Facilitators and barriers to survey participation by physicians: a call to action for researchers. *Eval Health Prof*. 2013; 36:279–295. [PubMed: 23975758]
- Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. *J Addict Med*. 2011; 5:21–27. [PubMed: 21359109]
- Koch AL, Arfken CL, Schuster CR. Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. *Drug Alcohol Depend*. 2006; 83:274–278. [PubMed: 16413146]
- Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. *J Addict Med*. 2014; 8:315–326. [PubMed: 25221984]

- Luce RD, Tukey JW. Simultaneous Conjoint-Measurement - a New Type of Fundamental Measurement. *J Math Psychol.* 1964; 1:1–27.
- McLellan AT, Woodworth AM. The Affordable Care Act and treatment for “substance use disorders:” Implications of ending segregated behavioral healthcare. *J Subst Abuse Treat.* 2014; 46:541–545. [PubMed: 24679908]
- McLeod CC, Klabunde CN, Willis GB, et al. Health care provider surveys in the United States, 2000–2010: a review. *Eval Health Prof.* 2013; 36:106–126. [PubMed: 23378504]
- Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. *J Subst Abuse Treat.* 2009; 36:244–251. [PubMed: 18715741]
- Nielsen S, Hillhouse M, Mooney L, et al. Buprenorphine pharmacotherapy and behavioral treatment: Comparison of outcomes among prescription opioid users, heroin users and combination users. *J Subst Abuse Treat.* 2015; 48:70–76. [PubMed: 25065489]
- Orme, BK. Getting started with conjoint analysis: Strategies for product design and pricing research. 2. Madison, WI: Research Publishers; 2010.
- Parran TV, Adelman CA, Merkin B, et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. *Drug Alcohol Depend.* 2010; 106:56–60. [PubMed: 19717249]
- Peabody JW, Luck J, Glassman P, et al. Comparison of vignettes, standardized patients, and chart abstraction - A prospective validation study of 3 methods for measuring quality. *JAMA.* 2000; 283:1715–1722. [PubMed: 10755498]
- Rieckmann TR, Kovas AE, McFarland BH, et al. A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment. *J Subst Abuse Treat.* 2011; 41:374–385. [PubMed: 21821379]
- Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. *Br Med J.* 2000; 320:1530–1533. [PubMed: 10834905]
- Sattler, H., Hensel-Borner, S. A comparison of conjoint measurement with self-explicated approaches. In: Gustafsson, A.Herrman, A., Huber, F., editors. *Conjoint measurement: Methods and applications.* New York: Springer; 2003. p. 121-134.
- Saxon AJ, Ling W, Hillhouse M, et al. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. *Drug Alcohol Depend.* 2013; 128:71–76. [PubMed: 22921476]
- Sommers AS, Paradise J, Miller C. Physician willingness and resources to serve more Medicaid patients: Perspectives from primary care physicians. *Medicare & Medicaid Research Review.* 2011; 1(2)doi: 10.5600/mmrr.5001.5602.a5601
- Sommers BD, Gunja MZ, Finegold K, et al. Changes in self-reported insurance coverage, access to care, and health under the Affordable Care Act. *JAMA.* 2015; 314:366–374. [PubMed: 26219054]
- Stevens EB, Jason LA. Evaluating alcoholics anonymous sponsor attributes using conjoint analysis. *Addict Behav.* 2015; 51:12–17. [PubMed: 26186375]
- Sullivan LE, Chawarski M, O'Connor PG, et al. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment? *Drug Alcohol Depend.* 2005; 79:113–116. [PubMed: 15943950]
- The Mental Health & Substance Use Disorder Parity Task Force. [Accessed March 3, 2017] Final Report. 2016. Available at: <http://web.archive.org/web/20170222054949/https://www.hhs.gov/sites/default/files/mental-health-substance-use-disorder-parity-task-force-final-report.PDF>
- Thomas CP, Reif S, Haq S, et al. Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. *Psychiatr Serv.* 2008; 59:909–916. [PubMed: 18678689]
- Torrington M, Domier CP, Hillhouse M, et al. Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting. *J Addict Dis.* 2007; 26:93–99. [PubMed: 18018812]
- Vergara-Rodriguez P, Tozzi MJ, Botsko M, et al. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. *J Acquir Immune Defic Syndr.* 2011; 56(Suppl 1):S62–67. [PubMed: 21317596]
- Volkow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies--Tackling the opioid-overdose epidemic. *N Engl J Med.* 2014; 370:2063–2066. [PubMed: 24758595]

- Willis, GB. Cognitive interviewing: A tool for improving questionnaire design. Thousand Oaks, CA: Sage; 2005.
- Yang A, Arfken CL, Johanson CE. Steps physicians report taking to reduce diversion of buprenorphine. *Am J Addict*. 2013; 22:184–187. [PubMed: 23617857]
- Young AM, Rudolph AE, Quillen D, et al. Spatial, temporal and relational patterns in respondent-driven sampling: evidence from a social network study of rural drug users. *J Epidemiol Community Health*. 2014; 68:792–798. [PubMed: 24692631]

Figure 1.

Average relative importance scores of seven attributes in buprenorphine prescribing decisions

Notes. Average relative importance scores sum to 100, thus allowing the magnitudes of these scores to be compared across the seven attributes.

Table 1

Professional and demographic characteristics of current buprenorphine prescribers (N=1,174)

	Mean (SD) or % (N)
Waiver type	
Up to 30 concurrent patients	42.2% (496)
Up to 100 concurrent patients	57.8% (678)
Delivers buprenorphine in an individual medical practice	50.8% (587)
Delivers buprenorphine in a group medical practice	35.2% (406)
Delivers buprenorphine in a Veterans Administration medical center (VAMC)	4.6% (53)
Delivers buprenorphine in a hospital (non-VAMC)	13.2% (152)
Delivers buprenorphine in an opioid treatment program (OTP)	6.2% (71)
Delivers buprenorphine in a substance use disorder program (non-OTP)	14.0% (161)
<i>Demographic characteristics</i>	
Medical specialty	
Addiction (i.e., addiction medicine, addiction psychiatry)	21.6% (248)
Psychiatry (with no mention of addiction)	27.2% (312)
Non-addiction/non-psychiatry	51.3% (589)
Female	22.9% (267)
Age in years	55.5 (11.4)
Race/ethnicity	
White	76.5% (878)
Asian	12.5% (144)
African American/Black	4.7% (54)
Hispanic	4.4% (50)
Multiracial/Other	1.9% (22)

* Notes. Some percentages may sum to greater than 100% due to rounding error. Physicians could indicate delivering buprenorphine in more than one practice setting. At the time of data collection, the 275-patient waiver had not been fully implemented.

Table 2

Combinations of levels in 20 vignettes of patients presenting for buprenorphine treatment

Patient Vignette	Opioid Type & Primary Route	Treatment History	Risky Substance Use	Co-Occurring Infections	Spousal Involvement	Employment Status	Method of Payment
1	Heroin; IV	4 th episode; hx of MMT	No hx AUD or BUD	HCV+ HIV–	Spouse uses opioids	Employed	Medicaid
2	Heroin; IV	1 st episode	Binge drinking	HCV+ HIV–	Hiding tx from spouse	Unemployed	Private insurance
3	Rx opioid; IV	1 st episode	Illicit alprazolam	HCV– HIV+	Spouse uses opioids	Employed	Cash
4	Rx opioid; IV	4 th episode; hx of MMT	Binge drinking	HCV– HIV+	Abstinent spouse	Employed	Private insurance
5	Rx opioid; IV	4 th episode; hx of OPDF	No hx AUD or BUD	HCV+ HIV–	Hiding tx from spouse	Employed	Cash
6	Heroin; IV	4 th episode; hx of MMT	Binge drinking	HCV– HIV–	Spouse uses opioids	Employed	Cash
7	Heroin; IV	4 th episode; hx of OPDF	No hx AUD or BUD	HCV– HIV+	Abstinent spouse	Unemployed	Cash
8	Heroin; IV	4 th episode; hx of OPDF	Illicit alprazolam	HCV– HIV–	Abstinent spouse	Employed	Private insurance
9	Rx opioid; non-IV	4 th episode; hx of OPDF	Illicit alprazolam	HCV+ HIV–	Spouse uses opioids	Employed	Private insurance
10	Rx opioid; IV	4 th episode; hx of OPDF	Binge drinking	HCV– HIV–	Hiding tx from spouse	Employed	Medicaid
11	Rx opioid; IV	4 th episode; hx of MMT	Illicit alprazolam	HCV+ HIV–	Abstinent spouse	Unemployed	Medicaid
12	Rx opioid; non-IV	1 st episode	No hx AUD or BUD	HCV– HIV–	Abstinent spouse	Employed	Medicaid
13	Heroin; IV	1 st episode	Illicit alprazolam	HCV– HIV+	Hiding tx from spouse	Employed	Medicaid
14	Rx opioid; non-IV	4 th episode; hx of MMT	Illicit alprazolam	HCV– HIV–	Hiding tx from spouse	Unemployed	Cash
15	Rx opioid; non-IV	4 th episode; hx of OPDF	Binge drinking	HCV– HIV+	Spouse uses opioids	Unemployed	Medicaid
16	Rx opioid; non-IV	1 st episode	Binge drinking	HCV+ HIV–	Abstinent spouse	Employed	Cash
17	Rx opioid; non-IV	4 th episode; hx of MMT	No hx AUD or BUD	HCV– HIV+	Hiding tx from spouse	Employed	Private insurance
18	Rx opioid; IV	1 st episode	No hx AUD or BUD	HCV– HIV–	Spouse uses opioids	Unemployed	Private insurance
19	Rx opioid; IV	4 th episode; hx of MMT	Binge drinking	HCV+ HIV–	Hiding tx from spouse	Unemployed	Cash
20	Heroin; IV	4 th episode; hx of OPDF	Binge drinking	HCV– HIV–	Hiding tx from spouse	Employed	Private insurance

Notes. Each vignette consisted of seven levels that were presented in bullet point format and then the two outcome ratings. Patients 19 and 20 represented the two holdouts, which were not used to calculate part-worth utilities. Abbreviations: IV=intravenous route. Rx opioid=prescription opioid. Hx=history. MMT=metadone maintenance. OPDF=outpatient drug-free clinic. AUD=alcohol use disorder. BUD=benzodiazepine use disorder. HCV=hepatitis C virus. HIV=human immunodeficiency virus. Tx=treatment.

Table 3

Descriptive statistics for 20 vignettes of patients presenting for buprenorphine treatment

	Rating 1 Willingness to Prescribe (Range=0–10)		Rating 2 Amount of Medication (Range=0–6)	
	Mean (SD)	Distribution	Mean (SD)	Distribution
PATIENT 1	5.28 (3.64)	0=21.0% 1–5=25.9% 6–9=37.4% 10=15.5%	1.99 (1.67)	None=22.2% <1 week=15.5% 1 week=36.3% 2 weeks=26.0%
PATIENT 2	5.28 (3.43)	0=17.6% 1–5=29.3% 6–9=40.8% 10=13.2%	1.97 (1.59)	None=19.7% <1 week=18.7% 1 week=35.7% 2 weeks=25.9%
PATIENT 3	5.11 (3.40)	0=15.9% 1–5=35.4% 6–9=35.4% 10=13.4%	1.93 (1.62)	None=20.3% <1 week=21.2% 1 week=32.9% 2 weeks=25.5%
PATIENT 4	5.93 (3.43)	0=15.6% 1–5=22.1% 6–9=44.9% 10=17.4%	2.16 (1.62)	None=15.9% <1 week=16.5% 1 week=37.3% 2 weeks=30.4%
PATIENT 5	7.11 (2.77)	0=5.0% 1–5=18.6% 6–9=51.7% 10=24.8%	2.45 (1.51)	None=5.3% <1 week=17.7% 1 week=42.5% 2 weeks=34.5%
PATIENT 6	5.64 (3.25)	0=11.6% 1–5=33.6% 6–9=39.9% 10=15.1%	2.07 (1.58)	None=14.9% <1 week=21.1% 1 week=37.1% 2 weeks=26.9%
PATIENT 7	7.62 (2.69)	0=4.7% 1–5=12.7% 6–9=50.0% 10=32.8%	2.54 (1.52)	None=4.9% <1 week=15.9% 1 week=42.2% 2 weeks=37.1%
PATIENT 8	5.31 (3.55)	0=19.6% 1–5=25.9% 6–9=39.9% 10=14.5%	2.04 (1.66)	None=20.6% <1 week=16.8% 1 week=34.2% 2 weeks=28.3%

	Rating 1 Willingness to Prescribe (Range=0–10)		Rating 2 Amount of Medication (Range=0–6)	
	Mean (SD)	Distribution	Mean (SD)	Distribution
PATIENT 9	4.55 (3.41)	0=21.4% 1–5=36.4% 6–9=32.6% 10=9.6%	1.83 (1.61)	None=23.7% <1 week=20.3% 1 week=32.6% 2 weeks=23.4%
PATIENT 10	4.65 (3.54)	0=24.4% 1–5=30.2% 6–9=35.0% 10=10.4%	1.85 (1.63)	None=24.9% <1 week=16.9% 1 week=34.0% 2 weeks=24.2%
PATIENT 11	4.43 (3.64)	0=28.1% 1–5=28.1% 6–9=32.9% 10=11.0%	1.77 (1.65)	None=28.7% <1 week=16.6% 1 week=30.9% 2 weeks=23.8%
PATIENT 12	6.51 (3.89)	0=19.2% 1–5=13.6% 6–9=33.0% 10=34.2%	2.18 (1.64)	None=18.4% <1 week=12.7% 1 week=36.5% 2 weeks=32.4%
PATIENT 13	4.14 (3.62)	0=31.0% 1–5=30.6% 6–9=28.3% 10=10.3%	1.61 (1.60)	None=31.8% <1 week=18.0% 1 week=30.2% 2 weeks=20.0%
PATIENT 14	5.14 (3.35)	0=15.4% 1–5=35.3% 6–9=36.3% 10=12.9%	2.00 (1.60)	None=17.8% <1 week=21.1% 1 week=34.4% 2 weeks=26.6%
PATIENT 15	4.18 (3.47)	0=28.0% 1–5=33.3% 6–9=30.3% 10=8.6%	1.71 (1.62)	None=28.6% <1 week=18.8% 1 week=31.3% 2 weeks=21.3%
PATIENT 16	6.87 (2.98)	0=6.2% 1–5=22.0% 6–9=49.0% 10=22.8%	2.39 (1.52)	None=7.3% <1 week=18.1% 1 week=39.7% 2 weeks=34.8%
PATIENT 17	6.15 (3.32)	0=13.4% 1–5=22.3% 6–9=45.3%	2.24 (1.58)	None=13.0% <1 week=16.4% 1 week=39.4%

	Rating 1 Willingness to Prescribe (Range=0–10)		Rating 2 Amount of Medication (Range=0–6)	
	Mean (SD)	Distribution	Mean (SD)	Distribution
		10=19.1%		2 weeks=31.2%
PATIENT 18	5.85 (3.46)	0=15.7% 1–5=24.0% 6–9=41.8% 10=18.6%	2.06 (1.54)	None=15.4% <1 week=19.8% 1 week=37.4% 2 weeks=27.3%
PATIENT 19	5.54 (3.20)	0=11.4% 1–5=35.4% 6–9=39.2% 10=14.1%	2.10 (1.54)	None=13.0% <1 week=21.9% 1 week=36.8% 2 weeks=28.3%
PATIENT 20	5.20 (3.42)	0=18.6% 1–5=29.2% 6–9=40.2% 10=12.0%	1.97 (1.59)	None=19.5% <1 week=18.7% 1 week=36.6% 2 weeks=25.3%

Notes. Vignettes were designed before the release of the DSM-5, which is why the words “dependence” and “abuse” were used. Outcome rating 1 asked respondents, “How likely are you to begin prescribing buprenorphine-naloxone to treat this patient?” on a scale ranging from 0=not at all likely to 10=extremely likely. Outcome rating 2 asked, “How many weeks of medication would you initially prescribe to this patient after induction?” with 7 response options (i.e., 0=none (would not induct), 1=<1 week, 2=1 week, 3=2 weeks, 4=3 weeks, 5=4 weeks, 6=>4 weeks). Patients 19 and 20 represented the two holdouts, which were not used to calculate part-worth utilities but were used for examine model reliability. Percentages may not sum to 100% due to rounding.

Table 4

Attributes and levels of conjoint vignettes with part-worth utilities for likelihood of prescribing buprenorphine (Outcome rating 1) and weeks of medication (Outcome rating 2)

Attribute	Levels within the Attribute	Rating 1 Part-worth Utility (Standard Error)	Rating 2 Part-worth Utility (Standard Error)
Type of opioid and primary route of administration	Heroin dependence (DSM-IV); primary route is intravenous	-.010 (.036)	-.010 (.008)
	Prescription opioid dependence (DSM-IV); primary route is intravenous	-.023 (.036)	-.011 (.008)
	Prescription opioid dependence (DSM-IV); primary route is non-intravenous	.033 (.036)	.021 (.008)
Treatment history	1 st time seeking treatment	.096 (.036)	-.024 (.008)
	4 th time seeking treatment; previous treatment at outpatient drug-free clinics	.042 (.036)	.036 (.008)
	4 th time seeking treatment; previous treatment has included methadone maintenance	-.139 (.036)	-.012 (.008)
Risky substance use	No history of alcohol or benzodiazepine use disorders	.947 (.036)	.281 (.008)
	No history of benzodiazepine abuse, but engages in weekly binge drinking	-.121 (.036)	-.016 (.008)
	No history of alcohol abuse, but weekly illicit alprazolam use	-.826 (.036)	-.264 (.008)
Co-occurring infections	HIV- and Hepatitis C-	-.021 (.036)	-.015 (.008)
	Hepatitis C+ and HIV -	.035 (.036)	.033 (.008)
	HIV+ and Hepatitis C-	-.014 (.036)	-.017 (.008)
Spousal involvement in treatment	Does not want spouse to know about treatment	-.139 (.036)	-.036 (.008)
	Spouse also abuses opioids but is not seeking treatment	-.480 (.036)	-.155 (.008)
	Spouse does not use drugs and is willing to supervise dosing	.619 (.036)	.192 (.008)
Employment status	Employed	.093 (.027)	.037 (.006)
	Unemployed	-.093 (.027)	-.037 (.006)
Method of payment for office visits	Has Medicaid to pay for office visits; cannot pay out-of-pocket	-.753 (.036)	-.261 (.008)
	Has private insurance to pay for office visits; cannot pay out-of-pocket	-.021 (.036)	.003 (.008)
	Willing to pay out-of-pocket (cash) for office visits	.774 (.036)	.258 (.008)
Constant		5.272 (.027)	1.846 (.006)

Notes. Part-worth utilities were calculated based on Patients 1–18. Higher part-worth utilities, which represent regression coefficients, were indicative of greater influence of attributes on physicians' responses. Rating 1 asked respondents, "How likely are you to begin prescribing buprenorphine-naloxone to treat this patient?" on a scale ranging from 0=not at all likely to 10=extremely likely. Rating 2

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

asked, “How many weeks of medication would you initially prescribe to this patient after induction?” with 7 response options (i.e., 0=none (would not induct), 1=<1 week, 2=1 week, 3=2 weeks, 4=3 weeks, 5=4 weeks, 6=>4 weeks). Analysis of the hold-out vignettes (Patients 19–20) indicated high correlations between predicted responses based on the conjoint model and responses to the hold-out vignettes. Vignettes were designed before the release of the DSM-5, which is why the words “dependence” and “abuse” were used.